| Literature DB >> 27144557 |
Lucas Amaral-Machado1,2,3, Francisco H Xavier-Júnior4, Renata Rutckeviski5, Andreza R V Morais6, Éverton N Alencar7, Teresa R F Dantas8, Ana K M Cruz9, Julieta Genre10, Arnóbio A da Silva-Junior11, Matheus F F Pedrosa12, Hugo A O Rocha13, Eryvaldo S T Egito14,15,16.
Abstract
Bullfrog oil is a natural product extracted from the Rana catesbeiana Shaw adipose tissue and used in folk medicine for the treatment of several diseases. The aim of this study was to evaluate the extraction process of bullfrog oil, to develop a suitable topical nanoemulsion and to evaluate its efficacy against melanoma cells. The oil samples were obtained by hot and organic solvent extraction processes and were characterized by titration techniques and gas chromatography mass spectrometry (GC-MS). The required hydrophile-lipophile balance and the pseudo-ternary phase diagram (PTPD) were assessed to determine the emulsification ability of the bullfrog oil. The anti-tumoral activity of the samples was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for normal fibroblast (3T3) and melanoma (B16F10) cell lines. Both extraction methods produced yielded around 60% and the oil was mainly composed of unsaturated compounds (around 60%). The bullfrog oil nanoemulsion obtained from PTPD presented a droplet size of about 390 nm and polydispersity = 0.05 and a zeta potential of about -25 mV. Both the bullfrog oil itself and its topical nanoemulsion did not show cytotoxicity in 3T3 linage. However, these systems showed growth inhibition in B16F10 cells. Finally, the bullfrog oil presented itself as a candidate for the development of pharmaceutical products free from cytotoxicity and effective for antineoplastic therapy.Entities:
Keywords: bullfrog oil; nanocarrier; nanomedicine; tumor cells
Mesh:
Substances:
Year: 2016 PMID: 27144557 PMCID: PMC6273763 DOI: 10.3390/molecules21050585
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Physicochemical parameters resulting from the analysis of bullfrog oil. Acid index (mg of KOH/g of oil); Saponification index (mg of KOH/g of oil), Iodine index (g of iodine absorbed/100 g of oil), and Peroxide index (mEq of active oxygen/1000 g of oil). Dark gray: bullfrog oil extracted by heating process (BOH); Light gray: bullfrog oil extracted by the organic solvent process (BOHx). * Statistical Difference.
Chemical characterization by GC-MS of the bullfrog oil obtained by hot extraction (BOH).
| Substance | Retention Time (min) | Concentration (%) |
|---|---|---|
| Myristic acid | 10.3 | 1.4 |
| Arachidonic acid | 12.0 | 8.4 |
| Palmitic acid | 12.2 | 10.3 |
| EPA, Timnodonic acid | 13.7 | 17.6 |
| Oleic acid | 13.7 | 29.9 |
| Stearic acid | 14 | 2.5 |
| DHA, Cervonic acid | 16.5 | 0.8 |
| Cholesterol | 20.6 | 9.5 |
| Ethyl iso-allocholate | 27.7 | 3.5 |
| Total | 83.9 | |
| Not identified | 16.1 |
GC-MS (gas chromatography mass spectrometry); EPA (eicosapentaenoic acid); DHA (docosahexaenoic acid).
Characterization of the first batch of nanoemulsion systems based on bullfrog oil to determine the HLBr after 60 days of evaluation at 25 °C.
| HLB | Droplet Size (nm) ± SD | Polydispersity | Micro-Emultocrit (%) ± SD | pH ± SD | Conductivity (S/cm) |
|---|---|---|---|---|---|
| 4.5 | PS | PS | PS | PS | PS |
| 5.5 | PS | PS | PS | PS | PS |
| 6.5 | PS | PS | PS | PS | PS |
| 7.5 | PS | PS | PS | PS | PS |
| 8.5 | 266.7 ± 14.2 | 0.235 | 4.1 ± 1.3 | 4.2 ± 0.6 | 94.4 |
| 9.5 | 257.7 ± 13.7 | 0.261 | 3.6 ± 1.2 | 3.9 ± 0.5 | 121.2 |
| 10.5 | 295.9 ± 24.8 | 0.268 | 4.3 ± 1.5 | 4.9 ± 1.0 | 107.7 |
| 11.5 | PS | PS | PS | PS | PS |
| 12.5 | 259.8 ± 8.7 | 0.218 | 3.0 ± 0.6 | 4.2 ± 0.6 | 100.3 |
| 13.5 | 275.6 ± 11.9 | 0.190 | 2.8 ± 0.7 | 3.8 ± 0.6 | 175.7 |
| 14.5 | 324.3 ± 26.0 | 0.230 | 3.6 ± 0.8 | 4.0 ± 0.4 | 101.4 |
| 15.5 | PS | PS | PS | PS | PS |
HLBr (required hydrophile-lipophile balance); SD (standard deviation); PS (phase separation).
Characterization of the second batch of nanoemulsion systems based on bullfrog oil to determine the HLBr after 60 days of evaluation at 25 °C.
| HLB | Droplet Size (nm) ± SD | Polydispersity | Micro-Emultocrit (%) ± SD | pH ± SD | Conductivity (S/cm) |
|---|---|---|---|---|---|
| 12.1 | 212.0 ± 13.6 | 0.213 | 2.4 ± 0.5 | 5.2 ± 1.4 | 91.2 |
| 12.2 | 202.7 ± 21.6 | 0.22 | 2.4 ± 0.5 | 5.1 ± 1.5 | 100.8 |
| 12.5 | 202.9 ± 29.8 | 0.215 | 2.2 ± 0.7 | 5.4 ± 1.2 | 87.3 |
| 12.7 | 199.6 ± 16.6 | 0.232 | 2.7 ± 0.4 | 5.1 ± 1.5 | 108.7 |
| 12.9 | 209.3 ± 18.4 | 0.234 | 2.1 ± 0.3 | 5.3 ± 1.4 | 97.4 |
| 13.0 | 196.4 ± 17.3 | 0.215 | 2.0 ± 0.0 | 5.2 ± 1.4 | 90.5 |
| 13.3 | 201.9 ± 15.0 | 0.215 | 2.5 ± 0.5 | 5.0 ± 1.5 | 100.1 |
| 13.5 | 208.1 ± 19.9 | 0.245 | 2.4 ± 0.5 | 5.1 ± 1.4 | 120.5 |
| 13.7 | 194.4 ± 11.7 | 0.225 | 2.4 ± 0.5 | 5.0 ± 1.5 | 72.5 |
| 13.9 | 193.7 ± 18.5 | 0.248 | 2.5 ± 0.5 | 5.0 ± 1.5 | 112.0 |
| 14.0 | 188.4 ± 22.2 | 0.261 | 2.7 ± 0.5 | 5.0 ± 1.5 | 120.4 |
HLBr (required hydrophile-lipophile balance); SD (standard deviation).
Figure 2Pseudo-ternary phase diagram of the bullfrog oil produced with HLBr 12.1. Black (phase separation), dark gray (microemulsion), medium gray (gel), white (emulsion).
Figure 3Droplet size and pH analyses for the basic emulsion and the topical nanoemulsion for 90 days. (A) droplet size analyses; (B) pH analyses. Dark gray: basic nanoemulsion; Light gray: topical nanoemulsion.
Figure 4Cell viability of the topical nanoemulsion and the bullfrog oil at three concentrations. (A) 3T3 cell viability; (B) B16F10 cell viability. Dark gray: 24 h; Light gray: 48 h; Medium gray: 72 h. * No statistical difference compared to the control. ** Statistical difference compared to the control.
Composition of the topical nanoemulsion.
| Excipients | % ( | Function | |
|---|---|---|---|
| 5.03 | Surfactant | ||
| 4.00 | Humectant | ||
| 0.30 | Antimicrobial preservative | ||
| 1.00 | Stabilizing agent | ||
| 62.55 | Dispenser agent | ||
| 2.97 | Surfactant | ||
| 0.10 | Antioxidant | ||
| 8.00 | Viscosity-increasing agent | ||
| 4.00 | Emollient and skin penetrant | ||
| 12.00 | Oil | ||
| 0.05 | Essence |